Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes by Mabb, Angela M. et al.
Angelman Syndrome: Insights into Genomic Imprinting and
Neurodevelopmental Phenotypes
Angela M. Mabb1,*, Matthew C. Judson1,*, Mark J. Zylka1,#, and Benjamin D. Philpot1,#
1Department of Cell and Molecular Physiology, UNC Neuroscience Center, and Carolina Institute
for Developmental Disabilities, University of North Carolina, Chapel Hill, NC 27599, USA
Abstract
Angelman syndrome (AS) is a severe genetic disorder caused by mutations or deletions of the
maternally inherited UBE3A gene. UBE3A encodes an E3 ubiquitin ligase that is expressed
biallelically in most tissues but is maternally expressed in almost all neurons. In this review, we
describe recent advances in understanding the expression and function of UBE3A in the brain and
the etiology of AS. We highlight current AS model systems, epigenetic mechanisms of UBE3A
regulation, and the identification of potential UBE3A substrates in the brain. In the process, we
identify major gaps in our knowledge that, if bridged, could move us closer to identifying
treatments for this debilitating neurodevelopmental disorder.
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Introduction to Angelman syndrome
Angelman Syndrome (AS) was originally described by Harry Angelman in 1965 and occurs
in approximately one out of every 12,000 births [1, 2]. Patients with AS exhibit
developmental delay, speech impairments, intellectual disability, epilepsy, abnormal EEGs
(electroencephalograms), puppet-like ataxic movements, prognathism, tongue protrusion,
paroxysms of laughter, abnormal sleep patterns, and hyperactivity [3]. Moreover, patients
with AS often exhibit socialization and communication deficits that meet the diagnostic
criteria for autism [2, 4], but it should be noted that autism diagnosis in AS can be
confounded by co-occurring developmental delay [5].
In most cases, AS is caused by mutations or deletions of the maternally inherited UBE3A
gene, which encodes a HECT (homologous to E6-associated protein C terminus) domain E3
ubiquitin ligase [6–8]. Because the paternal allele of UBE3A is epigenetically silenced (i.e.,
paternally imprinted) in most neurons but not other tissues (discussed below) [9–14],
maternal inactivation of UBE3A causes a nearly complete loss of UBE3A protein selectively
from the brain [14, 15]. AS typically (in ~75% of cases) arises from deletions (~6 Mb in
size) within chromosome 15q11-q13, a region that contains UBE3A. In ~15% of cases, the
maternal UBE3A allele alone is mutated [16], indicating that selective loss of brain UBE3A
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function can account for most AS phenotypes. A minority of AS cases arise from
microdeletions that affect imprinting at the 15q11-q13 locus (~2–4%) or from paternal
uniparental disomy (~7%), where two copies of an epigenetically silenced UBE3A allele are
inherited [17, 18]. Interestingly, while 15q11–q13 deletions cause AS, the most genetically
identifiable form of autism results from maternal duplication of the 15q11–q13 locus
encompassing UBE3A [19–22].
Although pharmacological options to control mood and sleep disorders have been partially
effective [23], in general, AS therapeutics have met with limited success. For example,
frequent seizures in AS patients are especially difficult to treat. There are AS patients with
unique seizure types and only a fraction of these individuals respond to pharmacological
intervention [24]. As another example, Levodopa (L-Dopa), which is commonly used to
treat Parkinsonian symptoms, is partially effective in treating late-onset movement disorders
in a subset of AS patients [25]. Moreover, efforts to unsilence the intact paternal UBE3A
allele with dietary supplements that increase DNA methylation have failed [26]. The paucity
of therapeutic options highlights a need to learn more about AS pathogenesis, the
mechanisms of imprinting, and downstream targets of UBE3A. Answers to these questions
could lead to development of novel AS therapeutics.
Here, we review recent progress in understanding the mechanisms of UBE3A imprinting,
how maternal UBE3A deficiency affects neurodevelopment, and how UBE3A protein
regulates substrates and binding partners. In addition, we discuss avenues for future
research, focusing on mouse models that are relevant to monitoring allelic expression of
UBE3A and to the discovery of synaptic and cognitive phenotypes that result from a loss of
UBE3A–substrate relationships.
Monitoring neuronal UBE3A imprinting
The genomic region spanning UBE3A, the UBE3A antisense transcript (UBE3A–ATS), and
the spliceosomal protein SNRPN (small nuclear ribonucleoprotein polypeptide N) [27]
contains a large number of imprinted genes that are either paternally or maternally expressed
in the human brain [27]. Mice possess a chromosomal region that is syntenic to human
15q11-q13 in which orthologous genes, including UBE3A, are also imprinted [28–30].
UBE3A is expressed from the maternal allele in most neurons, while the paternal allele is
intact but epigenetically silenced (Figure 1a) [9–13]. Initial studies indicate that the UBE3A
promoter region is unmethylated in mice and humans [17, 31], which may exclude
differential methylation of the UBE3A promoter as a mechanism for maternal expression.
Silencing of the paternal UBE3A allele is predominantly thought to be caused by expression
of a large (0.5–1.0 Mb) antisense RNA transcript (UBE3A–ATS) [10–12, 32]. As shown in
mice, this RNA transcript is paternally expressed in neurons [13, 33], initiates near the
differentially methylated Prader-Willi syndrome-imprinting center (PWS-IC), and runs
through Snurf (Snrpn upstream reading frame)/Snrpn and UBE3A (Figure 1a) [10, 34].
Moreover, snoRNAs (small nucleolar RNAs) expressed from gene clusters located between
UBE3A and Snurf/Snrpn [35] regulate neuronal nucleolar size [36], appear to be brain-
specific, and are paternally expressed (Figure 1a) [11, 37]. DNA methylation and histone
deacetylation at the maternal PWS-IC correlate with repression of the large transcript that
includes the UBE3A–ATS [32, 38–41]. Changes in these methylation and acetylation
patterns at the paternal PWS-IC locus are believed to permit production of the UBE3A–ATS
from the paternal allele [11, 32, 38–41] (Figure 1a). In mice, high resolution SNP (single-
nucleotide polymorphism) genotyping studies have demonstrated that only the 3’ end of
UBE3A is imprinted, while the 5’ end is biallelically expressed (Figure 1b) [33]. This
suggests a competition model involving UBE3A/UBE3A–ATS at the level of RNA-RNA
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interactions, such that the UBE3A–ATS somehow interferes with the production of a portion
of the UBE3A sense transcript in cis. However, other models of competitive interaction may
also contribute to paternal-specific regulation (Figure 1c) [42].
An antisense mechanism of regulation is further supported by studies using inter-subspecific
crosses of mice generating a 35 kb targeted deletion within the PWS-IC. Deletion of this
region in mice leads to upregulation of the paternal UBE3A allele, suggesting that this region
is required for paternal UBE3A silencing [32]. Replacing the mouse PWS-IC with the
corresponding human region produces a surprising outcome that also supports an antisense
mechanism of silencing. In this case, Ube3a–ATS is produced from paternal and maternal
alleles, resulting in silencing of both paternal and maternal UBE3A [43]. Biallelic expression
of the Ube3a–ATS could be due to reverse orientation selectivity of the human PWS-IC in
mouse or overall species variations in PWS-IC regulation [43].
Recently, a knock-in mouse in which a UBE3A–Yellow Fluorescent Protein (YFP) fusion
gene (Ube3aYFP) is expressed from either the maternal or paternal allele, was used to
monitor allelic contributions to UBE3A expression [44]. Paternal imprinting of UBE3A was
found in neurons in the hippocampus, cortex, thalamus, olfactory bulb, and cerebellum. The
UBE3A–YFP fusion protein was localized to the nucleus, with much lower levels of protein
in axons and dendrites of the hippocampus [44]. Biallelic expression of UBE3A–YFP was
observed in glial cells lining the lateral ventricles, confirming previous in vitro findings that
paternal imprinting does not manifest in all cell types in the brain [13]. Such a model may be
used to further characterize the distribution of paternal UBE3A expression in the brain
during development. These studies will help to reveal the ontogeny of paternal UBE3A
imprinting and, therefore, the earliest neurodevelopmental events that are susceptible to
maternal UBE3A deficiency.
Recent developments in understanding the mechanisms of UBE3A imprinting in human
patients have been obtained by studying induced pluripotent stem cell (iPSC) lines that were
established from individuals with AS [31]. UBE3A imprinting is retained in neurons derived
from both control iPSCs and AS patient iPSCs containing maternally-inherited deletions of
15q11-q13. In these stem cell-derived neurons, both maternal and paternal copies of the
PWS-IC retain their differential methylation patterns. Moreover, the UBE3A–ATS transcript
is expressed in iPSC-derived neurons, suggesting that the mechanisms of imprinting are
retained in iPSCs and are conserved from human to mouse. Thus, programmed
differentiation of human iPSCs could be useful for testing the mechanisms underlying
human gene imprinting and may allow one to identify mechanisms that relax imprinting.
AS mouse models recapitulate many AS patient phenotypes
To date, three AS mouse models have been engineered with targeted mutations that mimic
de novo chromosomal abnormalities underlying AS (Table 1). Because brain-specific
paternal imprinting of UBE3A also occurs in mice, all three models are based on the
maternal inheritance of a chromosomal deletion that includes UBE3A. Importantly, these
models recapitulate the loss of UBE3A in neurons in the central nervous system (CNS) [45–
47] and display several AS-relevant phenotypes [48–50]. Conversely, mice that inherit
paternal UBE3A deletions express normal levels of UBE3A in CNS neurons [45–47] and are
phenotypically normal [48, 50, 51].
The first mouse model of AS was generated by knocking out 3kb of sequence orthologous to
exon 2 of human UBE3A. This mutation causes a frame shift and results in a null allele [48].
Mice that carry this mutation on the maternal UBE3A allele (UBE3Am−/p+) display ataxia
and epilepsy [48, 52, 53]. The ataxia presents as abnormalities in gait, motor coordination,
motor learning [48, 51, 54], and reduced strength [54], which may model ataxia observed in
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patients with AS. These motor deficits are generally ascribed to a loss of cerebellar UBE3A
[52]; however, this has never been rigorously tested. Proprioceptive, spinal, and basal
ganglia circuits regulate motor function [55–57] and are just as likely to contribute to gait
disturbances when impaired. As a case in point, the extrapyramidal motor system may be
dysfunctional, since ~25% of dopaminergic neurons in the substantia nigra are lost in
UBE3Am−/p+ mice, and deficits in dopamine-sensitive motor tasks are observed [51].
UBE3Am−/p+ mice also exhibit audiogenic seizure susceptibility and have extended EEG
polyspike and slow wave discharges that co-occur with episodes of behavioral immobility
resembling absence epilepsy [48]. The penetrance and severity of seizures in UBE3Am−/p+
mice are influenced by genetic background [48], suggesting that this phenotype is modified
by other genes.
Motor deficits and EEG abnormalities are similarly found in a second AS mouse model. In
this model, the C-terminal sequence encoded by mouse UBE3A (corresponding to part of
exon 15 and all of exon 16 of human UBE3A) was replaced with a β-galactosidase (lacZ)
transcriptional reporter, resulting in a null allele [50]. Electrophysiological studies of these
mice indicate that motor dysfunction may be related to abnormal cerebellar output caused by
increased purkinje cell firing and rhythmicity [52]. Further EEG studies indicate sleep
abnormalities, such as reduced rapid eye movement (REM) sleep [58], which has been
reported in children with AS [59, 60]. Cognitive deficiency is another AS phenotype that has
been extensively modeled in these mice [50]. Consistent with learning impairments in
individuals with AS, these mice exhibit deficits in spatial learning and memory during
Morris water maze task performance and deficits in contextual fear conditioning [50]. These
learning impairments have also been observed in the original AS mouse model described
above [48, 53].
AS mouse models based on targeted UBE3A disruption have reinforced the hypothesis that
maternal UBE3A deficiency is the primary cause of AS. However, large maternal deletions
of chromosome 15q11-q13 manifest in the majority of AS cases and are correlated with
more severe clinical phenotypes [17, 23, 61], perhaps owing to the haploinsufficiency of
neighboring genes such as GABRB3 (GABAA receptor β3 subunit) and ATP10A (ATPase,
class V, type 10A) (Figure 1). For, example, Gabrb3 haploinsufficiency enhances seizure
susceptibility in mice [62], and thus may explain why epilepsy is more severe in AS patients
with large 15q11-q13 deletions than in individuals with UBE3A–specific insults [61]. Cre/
loxP and Hprt (hypoxanthine-guanine phosphoribosyltransferase) minigene chromosomal
engineering was recently employed to produce a mouse with a 1.6 Mb maternal deletion that
disrupts the Atp10a and Gabrb3 loci in addition to UBE3A [49]. This model may better
represent large deletion classes of AS. Like mice with targeted UBE3A deletions, large
deletion mice (deletionm−/p+) exhibit AS-relevant deficits, including EEG abnormalities and
motor and cognitive behavioral dysfunction [49] (Table 1). It will be informative to test
deletionm−/p+ mice for AS-relevant phenotypes that are not found in Ube3am−/p+ mice,
including hyperactivity and increased social-seeking [63]. Comparative studies between
deletionm−/p+ and UBE3Am−/p+ mice will help determine if the manifestation of these
phenotypes requires the haploinsufficiency of other neighboring genes (e.g., Gabrb3), or if
they are due to species-specific consequences of UBE3A loss. Future AS mouse models may
involve even larger deletions of the entire region syntenic with human 15q11-q13 and
approximate the ~6 Mb deletion found in many patients with AS. In the meantime, a current
model with transgenic replacement, rather than a true deletion, of the entire AS homology
region may prove useful in this regard [64, 65].
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Changes in neuronal morphology in AS mouse models
To help understand the profound neurological deficits underlying AS, researchers have
explored neuroanatomical correlates of abnormal connectivity and synaptic development in
UBE3Am−/p+ mice. These studies have almost exclusively focused on measuring dendritic
spines at the single-cell level owing to the fact that in vivo, UBE3A is localized to
postsynaptic compartments in addition to the nucleus [44]. Dendritic spine density (~15–
20%) and length (~10–15%) are reduced in post-adolescent UBE3Am−/p+ mice in cell
populations that may be relevant to cognitive deficits (i.e., pyramidal neurons in CA1 of the
hippocampus and in layer III-V of the cortex) and motor impairments (i.e., cerebellar
purkinje neurons) observed in AS [44]. In pre-adolescent mice, spine density deficits of a
similar magnitude are observed in the basal dendrites of layer II/III [45] and V [47]
pyramidal neurons in primary visual cortex. Interestingly, spine density appears normal in
the apical dendrites of these same layer V neurons, suggesting that UBE3A deficiency may
potentially influence synaptic development in a compartment-specific manner. This finding
contrasts with findings of reduced apical dendritic spine density in a previous study in which
neurons were broadly sampled from throughout the cortex of older, post-adolescent
UBE3Am−/p+ mice [44]. Therefore, it is possible that region- as well as age-specific
consequences of UBE3A deficiency contribute to synaptic abnormalities in AS. In general,
dendritic spine phenotypes in UBE3Am−/p+ mice are consistent with a role for UBE3A in
regulating excitatory postsynaptic development and function, which is only beginning to be
defined [66, 67].
Dendritic arborization has yet to be studied in a detailed, quantitative fashion in
UBE3Am−/p+ mice. Three key lines of evidence support that these and other basic studies of
neuronal morphology in this model are warranted. First, human postmortem findings
indicate that the dendritic arborization of cortical pyramidal neurons is decreased in AS [68].
Second, gross cortical and cerebellar weight is reduced (by ~15%) in both juvenile and
mature UBE3Am−/p+ mice [48], strongly suggesting that morphological abnormalities in
addition to decreased dendritic spine density are possible. Third, UBE3A expression is
coincident with developmental processes that precede synaptogenesis, including neuronal
migration and the establishment of polarity (i.e.,. axonogenesis, and dendritogenesis) [14].
These events collectively lay the cytoarchitectural foundation that supports possible
alterations in synaptic connectivity, function, and plasticity in AS, which we discuss below.
Changes in synaptic plasticity in AS mouse models
Early investigations of altered synaptic plasticity in UBE3Am−/p+ mice were inspired by
findings of impaired contextual fear conditioning, which led to studies of whether long-term
potentiation (LTP) of Schaffer collateral synapses in the CA1 hippocampal region was
impaired. Standard high-frequency stimulation protocols evoke only a transient potentiation
of these synapses in hippocampal slices from UBE3Am−/p+ mice [48]. However, sustained
LTP, similar to what was observed typically in wild-type mice, could be produced by
increasing slice temperature and the number of high-frequency stimulations [69]. This
suggests that the induction threshold for NMDA receptor- (NMDAR) dependent LTP is
increased at CA1 hippocampal synapses in UBE3Am−/p+ mice. NMDAR-independent LTP
is also more difficult to sustain in UBE3Am−/p+ slices [69], perhaps owing to deficient
signaling downstream of Ca2+ influx. Accordingly, a defect in Ca2+/calmodulin-dependent
protein kinase II (CaMKII) activation was found in the hippocampus of these mice [69].
This CaMKII activation defect correlates with chronic hyperphosphorylation at the
threonine (Thr286) autoactivation and Thr305 inhibitory sites of the CaMKII–α subunit.
However, these changes may be age- and or region-specific, as no evidence of altered
αCaMKII phosphorylation was found in the visual cortex of juvenile AS mice [47].
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Mutation of αCaMKII Thr305 to alanine in AS mice abrogates inhibitory αCaMKII
phosphorylation and, perhaps surprisingly, rescues both LTP and hippocampus-dependent
learning deficits [53]. The mechanism of CaMKII hyperphosphorylation in AS mice remains
elusive.
Deficits in neocortical synaptic development and plasticity in AS mice were first observed
within the visual cortex [45]. In this region, typical developmental increases in the frequency
of miniature excitatory postsynaptic currents (mEPSCs) are blunted in UBE3Am−/p+ layer II/
III pyramidal neurons. This finding corroborates measures of decreased dendritic spine
density [44, 45, 47], but contrasts with a more recent study reporting similar decreases in
mEPSC frequency without changes in synapse number in CA1 pyramidal neurons from
acute hippocampal slices [66]. Decreases in AMPA/NMDA current ratios and synaptic
AMPA receptor expression are also found in immature neurons cultured from UBE3Am−/p+
hippocampi [66]. This indicates that, at least in the hippocampus at young ages, UBE3A
deficiency may cause an increase in silent synapses (i.e., synapses lacking AMPA receptors)
rather than a loss of synapses per se.
It is intriguing to speculate that decreased spine densities in UBE3Am−/p+ mice might reflect
the end-point of an experience-driven, activity-dependent process whereby synapses
rendered silent at an early age are subsequently eliminated during later stages (Figure 2b).
Experience-dependent activity clearly influences the emergence of synaptic deficits
observed in Ube3am−/p+ mice. For example, dendritic spine deficits in pyramidal neurons of
layer II/III visual cortex fail to develop if Ube3am−/p+ mice are deprived of visual
experience [45]. Furthermore, LTP and LTD are not expressed at their normal induction
thresholds at layer IV to II/III synapses in slices of visual cortex from juvenile UBE3Am−/p+
mice, but late-onset visual deprivation rescues these synaptic plasticity deficits [45],
Moreover, this rescue is not maintained if visual experience is restored [45]. Thus,
experience is integral to the expression of plasticity deficits in the visual cortex of this AS
mouse model.
Experience-dependent activity may also alter the expression of UBE3A itself. Increased
rates of neuronal firing lead to increased levels of UBE3A through a process that requires
the activity-regulated transcription factor Mef2 (myocyte enhancement factor-2) [66].
However, UBE3A levels in primary visual cortex are not altered in response to monocular
deprivation [47], indicating that different paradigms of activity (e.g., neuronal firing patterns
vs. rates of activity) may be required to influence changes in UBE3A expression. Indeed,
treating cultured neurons with potassium chloride is well known to increase neuronal firing
rates, while monocular deprivation does not substantially alter visual cortical firing rates, but
only firing patterns [70]. Moreover, UBE3A may be subject to variable transcriptional
regulation during development, including during critical periods. Finally, as UBE3A appears
to target itself for proteasomal degradation [71–73], it may be that absolute measures of
UBE3A alone cannot be relied upon to identify time-points and/or anatomical regions where
UBE3A expression is altered. Detailed analysis of transcript:protein ratios may prove to be
more informative in this regard. New technologies to reliably measure UBE3A expression
and activity in the brain may illuminate temporal and regional UBE3A substrate specificity
and, ultimately, the understanding of AS etiology.
Identification of brain substrates for UBE3A
UBE3A is a HECT E3 ubiquitin ligase that ubiquitinates protein substrates, leading to their
degradation by the ubiquitin proteasome system (UPS) [74, 75]. Multiple mutations in
UBE3A have been attributed to defective UBE3A stability or catalytic function [23, 76]. The
ubiquitination and degradation of p53, the first identified substrate of UBE3A [77, 78],
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require not only UBE3A, but a viral cofactor E6, hence the initial naming of UBE3A as an
E6-associated protein (E6-AP) [77–80]. Notably, E6 is not required for UBE3A E3 ligase
activity, and E6 serves only as a bridging factor to facilitate the interaction of UBE3A with
certain substrates (such as p53). Although E6 is thought to be absent in the brain, increased
p53 levels in CA1 pyramidal neurons and purkinje cells in AS mice have been reported [48],
suggesting that E6-independent ubiquitination of p53 might occur. Loss of UBE3A has also
been shown to increase p53 levels in cultured Neuro2A cells [81]. However, UBE3A
regulation of p53 remains controversial, since p53 levels were found to be normal in one
UBE3A–deficient mouse line [50]. Later work described a DNA-repair enzyme, HHR23A
(human homologue A of Rad23) as the first E6-independent substrate for UBE3A in non-
neuronal tissue [82]. To date, no endogenous E6-like cofactors for UBE3A have been
described.
Drosophila express an ortholog of UBE3A, Dube3a, and can therefore be utilized as a model
system to genetically identify UBE3A–dependent substrates. Human UBE3A was
overexpressed in flies to examine potential decreases in protein content. The Rho-GEF
(guanine nucleotide exchange factor) Pbl (pebble) / ECT2 (epithelial cell transforming
sequence 2) was one of 20 proteins found to be differentially regulated when UBE3A was
overexpressed [83]. Furthermore, overexpressing human UBE3A could partially rescue the
rough eye phenotype in Pbl-overexpressing flies, suggesting that UBE3A attenuates Pbl
levels and that Pbl may be a UBE3A–dependent substrate.
Additionally, UBE3A has been implicated in regulating the cyclin dependent kinase
inhibitor p27, both in heterologous cells and in brain tissue [84]. UBE3A interacts with p27,
and promotes its ubiquitination in vitro [84]. Consistent with this finding, loss of UBE3A
results in decreased turnover of p27 in heterologous cells in vitro and leads to increases in
p27 protein levels in cerebellar purkinje, cortical, and hippocampal neurons [84]. Moreover,
a loss of UBE3A enhances p27 transcription in the cerebellum, suggesting that UBE3A not
only regulates the degradation and turnover of p27, but also its transcription [84]. In the
cortex, p27 promotes neuronal differentiation and migration in cortical projection neurons
[85]. Therefore, potentially increased levels of p27 in UBE3A–deficient mice might result in
the premature migration and differentiation of cortical neuronal progenitors and alter the
laminar architecture of the cortex. However, such a possibility awaits further experimental
testing.
The immediate early gene, Arc (activity-regulated cytoskeleton-associated protein), was also
recently characterized as a substrate for UBE3A [66, 86]. Arc is brain-specific and is rapidly
upregulated in response to increases in neuronal activity. Furthermore, Arc is known to
promote the endocytosis of AMPA receptors [87, 88] and is required for learning, long-term
memory, and homeostatic plasticity [86, 89–91]. UBE3A binds Arc in vivo and promotes its
ubiquitination in vitro [66]. Interestingly, seizure or learning protocols induce abnormally
elevated Arc expression in UBE3A knockout mice relative to wild-type controls [66],
suggesting that UBE3A is required for Arc turnover in the brain during bouts of elevated
synaptic activity. Changes in UBE3A levels correlate with surface expression of the AMPA
receptor subunit GluA1 that are inversely correlated with Arc levels, suggesting that UBE3A
regulates AMPAR endocytosis by controlling Arc protein levels (Figure 2) [66]. However, it
remains unclear if Arc ubiquitination is defective or if Arc has an extended half-life in the
AS brain. Intriguingly, basal levels of Arc increase during development [86]. It is tempting
to speculate that if UBE3A ubiquitinates Arc during critical periods for experience-
dependent plasticity, Arc levels in UBE3A–deficient neurons may increase to pathological
levels over a time course coincident with the onset of AS phenotypes (Figure 2).
Mabb et al. Page 7













Ephexin-5, a RhoA guanine nucleotide exchange factor (also known as Vsm-RhoGEF), is
another possible substrate for UBE3A [67, 92]. Ephexin-5 is highly expressed in the CNS,
where it interacts with the ephrin B2 receptor (EphB2) [67]. Ephexin-5 constitutively
activates RhoA, which leads to suppression of excitatory synapse number during
development [67]. Ephexin-5 null mice have increases in excitatory synapse number with
correlative increases in dendritic spine density [67]. The degradation of Ephexin-5 is
stimulated by Ephrin B binding to EphB2 and mediated by UBE3A [67]. Ephexin-5
degradation by UBE3A thus relieves the suppression of excitatory synapse development.
UBE3Am−/p+ mice have elevated levels of Ephexin-5 protein and decreased levels of
ubiquitinated Ephexin-5 [67], suggesting that UBE3A facilitates Ephexin-5 degradation.
Hence, the decreases in dendritic spine density identified in UBE3Am−/p+ mice [44, 45, 47]
may reflect defects in the degradation of Ephexin-5 by UBE3A (Figure 2). Interestingly,
both Ephexin-5 and Arc share a conserved UBE3A–binding domain sequence [66, 67],
indicating that a bioinformatics approach may be able to identify additional UBE3A
substrates (Table 2).
An additional factor adding to the potential complexity of this system is that three UBE3A
isoforms, resulting from differential splicing, have been reported [93]. Whether these three
isoforms have different functions in the brain has yet to be elucidated. However, a possible
complication in the identification and verification of UBE3A substrates stems from the
recent observation that isoform 2 of UBE3A is a binding partner for cytosolic and
synaptically isolated 26S proteasomes in the brain [94]. Depression of synaptic activity in
cultured hippocampal neurons, via a chemical LTD protocol, leads to the dissociation of
UBE3A from the proteasome and a subsequent reduction in UPS activity [94]. This suggests
that UBE3A may regulate overall proteasome activity following changes in synaptic
plasticity [94]. UBE3A isoforms 1 and 2 were also found to interact with purified
proteasome subunits in non-neuronal tissues [95–98]. Clearly, the role of UBE3A in
modulating proteasomal function and its ubiquitination of substrates will require further
analysis.
Conclusions and future directions
Although research is beginning to unveil the connections between UBE3A function and AS,
there are still fundamental questions remaining to be answered (Box 1). For instance, does
the UBE3A antisense mechanism fully account for why UBE3A is epigenetically silenced in
the brain but not other tissues? If yes, can expression of the functionally intact, but
epigenetically silenced, paternal UBE3A allele be upregulated by pharmacological means or
by genetically manipulating UBE3A–ATS transcription? Of equal importance, is
upregulation of UBE3A in the adult brain capable of rescuing neurodevelopmental and/or
cognitive deficits observed in AS? Or, does UBE3A need to be upregulated during critical
developmental periods? Answering these questions might provide clues to developing
therapeutic strategies for AS.
Another important question relates to how widespread UBE3A imprinting is in the nervous
system. Protein expression mapping in wild-type mice indicates variability in UBE3A levels
throughout the brain, within and among various neuron populations [46]. This variability
could be due to differential transcriptional/post-transcriptional regulation of maternal
UBE3A expression or relaxed paternal imprinting, possibly caused by variable overrun of
the maternal UBE3A transcript from the large Ube3a–ATS. In fact, there is evidence that
paternal imprinting is relaxed in visual cortex neurons prior to the critical period [47].
Detailed expression mapping of endogenous UBE3A expression in wild-type versus AS
mice, or maternal versus paternal UBE3A -YFP expression, will be required to reveal allelic
contributions to the heterogeneity of UBE3A expression in the nervous system.
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It is clear that interest in UBE3A for its role in AS has accelerated a new area of research and
has led to important insights into the role of UBE3A in neurons [99]. It is equally clear that
there are a number of critical gaps in our knowledge concerning the mechanisms of UBE3A
imprinting, the substrates of UBE3A, and the role that UBE3A plays in synaptic and circuit
function. By addressing these critical gaps, the field will move closer to identifying potential
therapeutic targets at which novel AS drugs could be directed.
Box 1: Outstanding Questions
• Why is UBE3A imprinted specifically in neurons?
• Does the UBE3A antisense mechanism fully account for neuron-specific
epigenetic silencing of UBE3A?
• What are the parameters for competition between sense and antisense transcripts
at the paternal UBE3A locus?
• Why do neurons with imprinted UBE3A expression show higher levels of
UBE3A than biallelically expressing cells [44]?
• How widespread is UBE3A imprinting in the nervous system? Does it occur in
the peripheral nervous system or is it restricted to the central nervous system?
• Can the study of neurons in which imprinting is relaxed inform us about the
mechanisms of UBE3A silencing?
• Can differential UBE3A levels within and among neural circuits tell us anything
about circuit vulnerability and the manifestation of characteristic AS
phenotypes?
• Why is neuronal UBE3A localization primarily nuclear while its major known
substrates are cytoplasmic?
• Is UBE3A function in the nucleus required for regulation of synaptic plasticity?
• 10.) How is the ubiquitin ligase activity of UBE3A regulated?
• 11.) Are there brain-specific E6-like factors that dictate substrate specificity for
UBE3A?
• 12.) Are there additional UBE3A substrates, and do they differ according to
subcellular compartment, cell type, brain region, and developmental period?
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Glossary
Allele One of two or more forms of a given DNA sequence of a gene
Genomic
Imprinting
A genetic process whereby genes are differentially expressed
depending on their parent-of-origin inheritance
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A behavioral paradigm where animals learn to fear a neutral stimulus
when paired with a noxious or painful stimulus. Brain regions
involved include the amygdala and, when cued by spatial context, the
hippocampus
Epigenetic: Heritable and reversible modifications to nucleotides or chromatin




A form of experience-dependent plasticity that occurs following
monocular visual deprivation whereby synaptic connections between
the deprived eye and the cortex are weakened or eliminated while
connections between the nondeprived eye and the cortex are
strengthened. This form of plasticity is most robust during critical
periods of postnatal development
Prader-Willi
syndrome:
An imprinting disorder that typically results from deletions within the
paternal copy of chromosome 15q11-q13. Note that deletions within
the maternal copy of this chromosomal region typically result in
Angelman syndrome
Prognathism Jaw malformation due to abnormal extension or bulging of the lower
jaw
References
1. Bower BD, Jeavons PM. The "happy puppet" syndrome. Arch Dis Child. 1967; 42(223):298–302.
[PubMed: 6025370]
2. Steffenburg S, et al. Autism in Angelman syndrome: a population-based study. Pediatr Neurol.
1996; 14(2):131–136. [PubMed: 8703225]
3. Williams CA, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med
Genet A. 2006; 140(5):413–418. [PubMed: 16470747]
4. Peters SU, et al. Autism in Angelman syndrome: implications for autism research. Clin Genet. 2004;
66(6):530–536. [PubMed: 15521981]
5. Trillingsgaard A, JR OS. Autism in Angelman syndrome: an exploration of comorbidity. Autism.
2004; 8(2):163–174. [PubMed: 15165432]
6. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat
Genet. 1997; 15(1):70–73. [PubMed: 8988171]
7. Sutcliffe JS, et al. The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed
Angelman syndrome critical region. Genome Res. 1997; 7(4):368–377. [PubMed: 9110176]
8. Matsuura T, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in
Angelman syndrome. Nat Genet. 1997; 15(1):74–77. [PubMed: 8988172]
9. Landers M, et al. Regulation of the large (approximately 1000 kb) imprinted murine Ube3a
antisense transcript by alternative exons upstream of Snurf/Snrpn. Nucleic Acids Res. 2004; 32(11):
3480–3492. [PubMed: 15226413]
10. Rougeulle C, et al. An imprinted antisense RNA overlaps UBE3A and a second maternally
expressed transcript. Nat Genet. 1998; 19(1):15–16. [PubMed: 9590281]
11. Runte M, et al. The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar
RNA species and as an antisense RNA for UBE3A. Hum Mol Genet. 2001; 10(23):2687–2700.
[PubMed: 11726556]
12. Runte M, et al. SNURF-SNRPN and UBE3A transcript levels in patients with Angelman
syndrome. Hum Genet. 2004; 114(6):553–561. [PubMed: 15014980]
13. Yamasaki K, et al. Neurons but not glial cells show reciprocal imprinting of sense and antisense
transcripts of Ube3a. Hum Mol Genet. 2003; 12(8):837–847. [PubMed: 12668607]
Mabb et al. Page 10













14. Albrecht U, et al. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in
hippocampal and Purkinje neurons. Nat Genet. 1997; 17(1):75–78. [PubMed: 9288101]
15. Jiang Y, et al. Imprinting in Angelman and Prader-Willi syndromes. Curr Opin Genet Dev. 1998;
8(3):334–342. [PubMed: 9691003]
16. Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet
Med. 2010; 12(7):385–395. [PubMed: 20445456]
17. Lossie AC, et al. Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J
Med Genet. 2001; 38(12):834–845. [PubMed: 11748306]
18. Buiting K, et al. Expressed copies of the MN7 (D15F37) gene family map close to the common
deletion breakpoints in the Prader-Willi/Angelman syndromes. Cytogenet Cell Genet. 1998; 81(3–
4):247–253. [PubMed: 9730612]
19. Cook EH Jr, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q
duplication. Am J Hum Genet. 1997; 60(4):928–934. [PubMed: 9106540]
20. Browne CE, et al. Inherited interstitial duplications of proximal 15q: genotype-phenotype
correlations. Am J Hum Genet. 1997; 61(6):1342–1352. [PubMed: 9399882]
21. Mao R, et al. Characteristics of two cases with dup(15)(q11.2–q12): one of maternal and one of
paternal origin. Genet Med. 2000; 2(2):131–135. [PubMed: 11397326]
22. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new
neurobiology. Nat Rev Genet. 2008; 9(5):341–355. [PubMed: 18414403]
23. Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J Med
Genet. 2003; 40(2):87–95. [PubMed: 12566516]
24. Pelc K, et al. Epilepsy in Angelman syndrome. Seizure. 2008; 17(3):211–217. [PubMed:
17904873]
25. Harbord M. Levodopa responsive Parkinsonism in adults with Angelman Syndrome. J Clin
Neurosci. 2001; 8(5):421–422. [PubMed: 11535008]
26. Peters SU, et al. Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid.
Am J Med Genet A. 2010; 152A(8):1994–2001. [PubMed: 20635355]
27. Lalande M, Calciano MA. Molecular epigenetics of Angelman syndrome. Cell Mol Life Sci. 2007;
64(7–8):947–960. [PubMed: 17347796]
28. Gregg C, et al. Sex-specific parent-of-origin allelic expression in the mouse brain. Science. 2010;
329(5992):682–685. [PubMed: 20616234]
29. Gregg C, et al. High-resolution analysis of parent-of-origin allelic expression in the mouse brain.
Science. 2010; 329(5992):643–648. [PubMed: 20616232]
30. Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and
Angelman syndromes. Annu Rev Genomics Hum Genet. 2001; 2:153–175. [PubMed: 11701647]
31. Chamberlain SJ, et al. Induced pluripotent stem cell models of the genomic imprinting disorders
Angelman and Prader-Willi syndromes. Proc Natl Acad Sci U S A. 2010; 107(41):17668–17673.
[PubMed: 20876107]
32. Chamberlain SJ, Brannan CI. The Prader-Willi syndrome imprinting center activates the paternally
expressed murine Ube3a antisense transcript but represses paternal Ube3a. Genomics. 2001; 73(3):
316–322. [PubMed: 11350123]
33. Numata K, et al. Highly parallel SNP genotyping reveals high-resolution landscape of mono-allelic
Ube3a expression associated with locus-wide antisense transcription. Nucleic Acids Res. 2010
34. Watanabe Y, et al. Genome-wide analysis of expression modes and DNA methylation status at
sense-antisense transcript loci in mouse. Genomics. 2010; 96(6):333–341. [PubMed: 20736060]
35. Vitali P, et al. Long nuclear-retained non-coding RNAs and allele-specific higher-order chromatin
organization at imprinted snoRNA gene arrays. J Cell Sci. 2010; 123(Pt 1):70–83. [PubMed:
20016068]
36. Leung KN, et al. Imprinting regulates mammalian snoRNA-encoding chromatin decondensation
and neuronal nucleolar size. Hum Mol Genet. 2009; 18(22):4227–4238. [PubMed: 19656775]
37. Cavaille J, et al. Identification of brain-specific and imprinted small nucleolar RNA genes
exhibiting an unusual genomic organization. Proc Natl Acad Sci U S A. 2000; 97(26):14311–
14316. [PubMed: 11106375]
Mabb et al. Page 11













38. Xin Z, Allis CD, Wagstaff J. Parent-specific complementary patterns of histone H3 lysine 9 and
H3 lysine 4 methylation at the Prader-Willi syndrome imprinting center. Am J Hum Genet. 2001;
69(6):1389–1394. [PubMed: 11592036]
39. Perk J, et al. The imprinting mechanism of the Prader-Willi/Angelman regional control center.
EMBO J. 2002; 21(21):5807–5814. [PubMed: 12411498]
40. Fulmer-Smentek SB, Francke U. Association of acetylated histones with paternally expressed
genes in the Prader--Willi deletion region. Hum Mol Genet. 2001; 10(6):645–652. [PubMed:
11230184]
41. Saitoh S, Wada T. Parent-of-origin specific histone acetylation and reactivation of a key imprinted
gene locus in Prader-Willi syndrome. Am J Hum Genet. 2000; 66(6):1958–1962. [PubMed:
10775525]
42. Faghihi MA, Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell
Biol. 2009; 10(9):637–643. [PubMed: 19638999]
43. Johnstone KA, et al. A human imprinting centre demonstrates conserved acquisition but diverged
maintenance of imprinting in a mouse model for Angelman syndrome imprinting defects. Hum
Mol Genet. 2006; 15(3):393–404. [PubMed: 16368707]
44. Dindot SV, et al. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus,
and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet. 2008;
17(1):111–118. [PubMed: 17940072]
45. Yashiro K, et al. Ube3a is required for experience-dependent maturation of the neocortex. Nat
Neurosci. 2009; 12(6):777–783. [PubMed: 19430469]
46. Gustin RM, et al. Tissue-specific variation of Ube3a protein expression in rodents and in a mouse
model of Angelman syndrome. Neurobiol Dis. 2010; 39(3):283–291. [PubMed: 20423730]
47. Sato M, Stryker MP. Genomic imprinting of experience-dependent cortical plasticity by the
ubiquitin ligase gene Ube3a. Proc Natl Acad Sci U S A. 2010; 107(12):5611–5616. [PubMed:
20212164]
48. Jiang YH, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic
p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998; 21(4):799–811.
[PubMed: 9808466]
49. Jiang YH, et al. Altered ultrasonic vocalization and impaired learning and memory in Angelman
syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3. PLoS One. 2010;
5(8)
50. Miura K, et al. Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-
deficient mice. Neurobiol Dis. 2002; 9(2):149–159. [PubMed: 11895368]
51. Mulherkar SA, Jana NR. Loss of dopaminergic neurons and resulting behavioural deficits in mouse
model of Angelman syndrome. Neurobiol Dis. 2010; 40(3):586–592. [PubMed: 20696245]
52. Cheron G, et al. Fast cerebellar oscillation associated with ataxia in a mouse model of Angelman
syndrome. Neuroscience. 2005; 130(3):631–637. [PubMed: 15590147]
53. van Woerden GM, et al. Rescue of neurological deficits in a mouse model for Angelman syndrome
by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci. 2007; 10(3):280–282.
[PubMed: 17259980]
54. Heck DH, et al. Analysis of cerebellar function in Ube3a–deficient mice reveals novel genotype-
specific behaviors. Hum Mol Genet. 2008; 17(14):2181–2189. [PubMed: 18413322]
55. Arber S, et al. ETS gene Er81 controls the formation of functional connections between group Ia
sensory afferents and motor neurons. Cell. 2000; 101(5):485–498. [PubMed: 10850491]
56. Hantman AW, Jessell TM. Clarke's column neurons as the focus of a corticospinal corollary
circuit. Nat Neurosci. 2010; 13(10):1233–1239. [PubMed: 20835249]
57. Kravitz AV, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal
ganglia circuitry. Nature. 2010; 466(7306):622–626. [PubMed: 20613723]
58. Colas D, et al. Sleep disturbances in Ube3a maternal-deficient mice modeling Angelman
syndrome. Neurobiol Dis. 2005; 20(2):471–478. [PubMed: 15921919]
59. Bruni O, et al. Sleep disturbances in Angelman syndrome: a questionnaire study. Brain Dev. 2004;
26(4):233–240. [PubMed: 15130689]
Mabb et al. Page 12













60. Miano S, et al. Sleep polygraphy in Angelman syndrome. Clin Neurophysiol. 2004; 115(4):938–
945. [PubMed: 15003776]
61. Minassian BA, et al. Angelman syndrome: correlations between epilepsy phenotypes and
genotypes. Ann Neurol. 1998; 43(4):485–493. [PubMed: 9546330]
62. DeLorey TM, et al. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy
phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci. 1998;
18(20):8505–8514. [PubMed: 9763493]
63. Allensworth M, et al. Normal social seeking behavior, hypoactivity and reduced exploratory range
in a mouse model of Angelman syndrome. BMC Genet. 2011; 12(1):7. [PubMed: 21235769]
64. Gabriel JM, et al. A transgene insertion creating a heritable chromosome deletion mouse model of
Prader-Willi and angelman syndromes. Proc Natl Acad Sci U S A. 1999; 96(16):9258–9263.
[PubMed: 10430930]
65. Stefan M, et al. Genetic mapping of putative Chrna7 and Luzp2 neuronal transcriptional enhancers
due to impact of a transgene-insertion and 6.8 Mb deletion in a mouse model of Prader-Willi and
Angelman syndromes. BMC Genomics. 2005; 6:157. [PubMed: 16280085]
66. Greer PL, et al. The Angelman Syndrome protein Ube3A regulates synapse development by
ubiquitinating arc. Cell. 2010; 140(5):704–716. [PubMed: 20211139]
67. Margolis SS, et al. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a
developmental brake on excitatory synapse formation. Cell. 2010; 143(3):442–455. [PubMed:
21029865]
68. Jay V, et al. Puppet-like syndrome of Angelman: a pathologic and neurochemical study.
Neurology. 1991; 41(3):416–422. [PubMed: 2006012]
69. Weeber EJ, et al. Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in
a mouse model for Angelman mental retardation syndrome. J Neurosci. 2003; 23(7):2634–2644.
[PubMed: 12684449]
70. Linden ML, et al. Thalamic activity that drives visual cortical plasticity. Nat Neurosci. 2009; 12(4):
390–392. [PubMed: 19252494]
71. Nuber U, Schwarz SE, Scheffner M. The ubiquitin-protein ligase E6-associated protein (E6-AP)
serves as its own substrate. Eur J Biochem. 1998; 254(3):643–649. [PubMed: 9688277]
72. Kao WH, et al. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP
ubiquitin-protein ligase. J Virol. 2000; 74(14):6408–6417. [PubMed: 10864652]
73. Crinelli R, et al. Ubiquitin over-expression promotes E6AP autodegradation and reactivation of the
p53/MDM2 pathway in HeLa cells. Mol Cell Biochem. 2008; 318(1–2):129–145. [PubMed:
18612801]
74. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009; 78:399–
434. [PubMed: 19489725]
75. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol
Cell Biol. 2009; 10(6):398–409. [PubMed: 19436320]
76. Cooper EM, et al. Biochemical analysis of Angelman syndrome-associated mutations in the E3
ubiquitin ligase E6-associated protein. J Biol Chem. 2004; 279(39):41208–41217. [PubMed:
15263005]
77. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the
E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991; 10(13):4129–4135.
[PubMed: 1661671]
78. Scheffner M, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in
the ubiquitination of p53. Cell. 1993; 75(3):495–505. [PubMed: 8221889]
79. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human
papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol
Cell Biol. 1993; 13(8):4918–4927. [PubMed: 8393140]
80. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a
protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol
Cell Biol. 1993; 13(2):775–784. [PubMed: 8380895]
Mabb et al. Page 13













81. Mishra A, et al. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation
and suppresses polyglutamine protein aggregation and toxicity. J Biol Chem. 2008; 283(12):7648–
7656. [PubMed: 18201976]
82. Kumar S, Talis AL, Howley PM. Identification of HHR23A as a substrate for E6-associated
protein-mediated ubiquitination. J Biol Chem. 1999; 274(26):18785–18792. [PubMed: 10373495]
83. Reiter LT, et al. Expression of the Rho-GEF Pbl/ECT2 is regulated by the UBE3A E3 ubiquitin
ligase. Hum Mol Genet. 2006; 15(18):2825–2835. [PubMed: 16905559]
84. Mishra A, Godavarthi SK, Jana NR. UBE3A/E6-AP regulates cell proliferation by promoting
proteasomal degradation of p27. Neurobiol Dis. 2009; 36(1):26–34. [PubMed: 19591933]
85. Nguyen L, et al. p27kip1 independently promotes neuronal differentiation and migration in the
cerebral cortex. Genes Dev. 2006; 20(11):1511–1524. [PubMed: 16705040]
86. Lyford GL, et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-
associated protein that is enriched in neuronal dendrites. Neuron. 1995; 14(2):433–445. [PubMed:
7857651]
87. Chowdhury S, et al. Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor
trafficking. Neuron. 2006; 52(3):445–459. [PubMed: 17088211]
88. Waung MW, et al. Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD
through persistent increases in AMPAR endocytosis rate. Neuron. 2008; 59(1):84–97. [PubMed:
18614031]
89. Steward O, et al. Synaptic activation causes the mRNA for the IEG Arc to localize selectively near
activated postsynaptic sites on dendrites. Neuron. 1998; 21(4):741–751. [PubMed: 9808461]
90. Plath N, et al. Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories.
Neuron. 2006; 52(3):437–444. [PubMed: 17088210]
91. Shepherd JD, et al. Arc/Arg3.1 mediates homeostatic synaptic scaling of AMPA receptors.
Neuron. 2006; 52(3):475–484. [PubMed: 17088213]
92. Ogita H, et al. EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in
vascular smooth muscle cells. Circ Res. 2003; 93(1):23–31. [PubMed: 12775584]
93. Yamamoto Y, Huibregtse JM, Howley PM. The human E6-AP gene (UBE3A) encodes three
potential protein isoforms generated by differential splicing. Genomics. 1997; 41(2):263–266.
[PubMed: 9143503]
94. Tai HC, et al. Characterization of the Brain 26S Proteasome and its Interacting Proteins. Front Mol
Neurosci. 2010; 3
95. Besche HC, et al. Isolation of mammalian 26S proteasomes and p97/VCP complexes using the
ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins. Biochemistry.
2009; 48(11):2538–2549. [PubMed: 19182904]
96. Scanlon TC, et al. Isolation of human proteasomes and putative proteasome-interacting proteins
using a novel affinity chromatography method. Exp Cell Res. 2009; 315(2):176–189. [PubMed:
19013454]
97. Wang X, et al. Mass spectrometric characterization of the affinity-purified human 26S proteasome
complex. Biochemistry. 2007; 46(11):3553–3565. [PubMed: 17323924]
98. Wang X, Huang L. Identifying dynamic interactors of protein complexes by quantitative mass
spectrometry. Mol Cell Proteomics. 2008; 7(1):46–57. [PubMed: 17934176]
99. Philpot B, et al. Angelman syndrome: advancing the research frontier of neurodevelopmental
disorders. Journal of Neurodevelopmental Disorders. 2011:50–56. [PubMed: 21484597]
100. Mohammad F, Mondal T, Kanduri C. Epigenetics of imprinted long noncoding RNAs.
Epigenetics. 2009; 4(5):277–286. [PubMed: 19617707]
101. Tedeschi A, Di Giovanni S. The non-apoptotic role of p53 in neuronal biology: enlightening the
dark side of the moon. EMBO Rep. 2009; 10(6):576–583. [PubMed: 19424293]
102. Mishra A, Jana NR. Regulation of turnover of tumor suppressor p53 and cell growth by E6-AP, a
ubiquitin protein ligase mutated in Angelman mental retardation syndrome. Cell Mol Life Sci.
2008; 65(4):656–666. [PubMed: 18193166]
Mabb et al. Page 14













103. Salzberg A, et al. P-element insertion alleles of essential genes on the third chromosome of
Drosophila melanogaster: mutations affecting embryonic PNS development. Genetics. 1997;
147(4):1723–1741. [PubMed: 9409832]
104. Mulherkar SA, Sharma J, Jana NR. The ubiquitin ligase E6-AP promotes degradation of alpha-
synuclein. J Neurochem. 2009; 110(6):1955–1964. [PubMed: 19645749]
Mabb et al. Page 15














Possible mechanisms for UBE3A imprinting in the brain. a. A map of the maternal (MAT)
and paternal (PAT) human chromosome region 15q11-q13 containing UBE3A, adapted from
Lalande and Calciano [27]. Maternally expressed genes are depicted in red and paternally
expressed genes are depicted in blue. Non-imprinted genes are represented in green. Top:
Methylation at the maternal PWS imprinting center (PWS-IC, black circle) globally
represses expression of surrounding genes (gray boxes), including the UBE3A antisense
(UBE3A–ATS) transcript. However, the maternal copy of UBE3A is expressed (red arrow).
Bottom: On the paternal chromosome, the PWS-IC contains a cluster of CpG sites that are
unmethylated (open circle), permitting paternal gene expression (blue boxes), including the
UBE3A–ATS transcript (blue arrow). The UBE3A–ATS (0.5–1.0 Mb in length) overlaps the
paternal UBE3A locus, resulting in transcriptional silencing of UBE3A (red arrow fading to
white). Open triangles represent the AS imprinting center (AS-IC). Neighboring genes
upstream of UBE3A include: NDN (necdin) and genes encoding snoRNAs [SNRPN PAR5
(Prader-Willi Angelman Syndrome region 5), HBII-8527 HBII-5247 and IPW (Imprinted in
Prader-Willi syndrome)]. Neighboring genes downstream of UBE3A include: ATP10A, the
GABAA receptor β3, α5 and γ2 subunits (GABRB3, GABRA5, GABRG3), OCA2
(Oculocutaneous albinism II) and HERC2 (Hect domain and RDL 2). b. Zoomed in region
from a depicting a cutoff (dashed vertical blue line) beyond which the silencing of UBE3A
transcription by the UBE3A–ATS is incomplete [33]. Left of the line, the UBE3A–ATS
transcript (dark blue shading) competes with the sense transcript (light red shading),
resulting in silencing of full-length UBE3A sense transcripts. In contrast, to the right of the
line, truncated paternal 5’ segments of the UBE3A sense transcripts (red) are produced [33].
c. Hypothetical mechanisms of UBE3A–ATS/sense competition at the paternal allele. Top:
Collision model [42]. If transcription can only occur in one direction at a single time, RNA
polymerases (RNAPII) transcribing the UBE3A sense strand (red) are competed off of their
templates by oncoming complexes engaged in transcription of the UBE3A–ATS strand
(blue). Bottom: RNA-DNA interaction model [42]. Production of the UBE3A–ATS induces
histone modifications (HM) that modify chromatin architecture along the UBE3A locus.
Transcriptional elongation of UBE3A is prematurely aborted at these regions, yielding
truncated UBE3A sense transcripts (red). Note that similar models of RNA regulation have
been described for genomic imprinting at other loci, such as Xist, a non-coding RNA
(ncRNA) that contributes to X chromosome inactivation and Air, a paternally expressed
ncRNA that leads to silencing of paternal insulin-like growth factor 2 receptor (Igf2r) [100].
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Schematic model illustrating the potential contribution of UBE3A to neuronal morphology
and developing neural circuits. a. During synaptogenesis, UBE3A ubiquitinates and
promotes the degradation of the RhoA-GEF Ephexin-5 by the UPS [67] leading to
inactivation of RhoA and facilitates formation of dendritic spines (highlighted in blue).
UBE3A also ubiquitinates and promotes the degradation of Arc [66], an immediate early
gene that facilitates the experience-dependent remodeling of pre-existing synapses by
mediating AMPA receptor (AMPAR) endocytosis [87, 88]. This remodeling allows
functional neural circuits to arise during development. Red circles, synapse elimination;
yellow circles, growth of new spines. bUBE3A deficiency results in the accumulation of
Ephexin-5 and Arc, as observed in the Ube3am−/p+ mice [66, 67]. Increased Ephexin-5
levels lead to an enhancement in active RhoA levels, which results in deficits in excitatory
synapse formation [67]. Inappropriately high accumulation of Arc leads to excessive
endocytosis of GluA1-containing AMPARs from glutamatergic synaptic sites [66], hence
reducing excitatory synaptic transmission. This also increases the number of silent
(AMPAR-lacking) synapses, which may subsequently be eliminated during experience-
dependent synapse remodeling. The resulting synaptic and circuit dysfunction may underlie
various AS phenotypes, including learning deficits, ataxia, seizures and impaired social/
communication skills.
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